Beta vulgaris ‐derived exosome‐like nanovesicles alleviate chronic doxorubicin‐induced cardiotoxicity by inhibiting ferroptosis

Dose‐dependent heart failure is a major complication of the clinical use of doxorubicin (Dox), one of the most potent chemotherapeutic agents. Effective adjuvant therapy is required to prevent Dox‐induced cardiotoxicity. Currently, plant‐derived exosome‐like nanovesicle (PELNV) has revealed their salubrious antioxidant and immunological regulating actions in various disease models. In this study, we isolated, purified and characterized Beta vulgaris ‐derived exosome‐like nanovesicle (BELNV). Dox or normal saline was given to HL‐1 cells (3 μM) and 8‐week C57BL/6N mice (5 mg/kg bodyweight per week for 4 weeks) to establish the in vitro and in vivo model of Dox‐induced cardiotoxicity. Administration of BELNV significantly alleviated chronic Dox‐induced cardiotoxicity in terms of echocardiographic and histological results. A reduced malondialdehyde (MDA), increased ratio of glutathione (GSH) to oxidized glutathione (GSSG) and levels of system xc − and glutathione peroxidase 4 were observed, indicating that DOX‐stimulated ferroptosis was reversed by BELNV. Besides, the safety of BELNV was also validated since no liver, spleen, and kidney toxicity induced by BELNV was observed. These findings provide evidence that BELNV may act as a novel therapeutic biomaterial for patients undergoing adverse effects of Dox, at least partly mediated by inhibiting Dox‐induced ferroptosis.